KFDA approved compassionate use of Iressa.

The KFDA approved Astra-Zeneca's Iressa, a cancer drug, for a compassionate use in treatment of advanced non cellular lung cancer. Iressa is a new anti-tumor drug still under phase III clinical studies in the United States and expected to be released in the commercial market around the first half of next year. However, the KFDA granted its compassionate use to Korean patients who are suffering ...